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Summary 
Background In metastatic renal cell carcinoma combinations of interferon alfa-2a, interleukin-2, and ﬂ uorouracil 
produce higher response rates and longer progression-free survival than do single agents. We aimed to compare 
overall survival in patients receiving combination treatment or interferon alfa-2a.
Methods RE04/30012 was an open-label randomised trial undertaken in 50 centres across eight countries. 
1006 treatment-naive patients diagnosed with advanced metastatic renal cell carcinoma were randomly allocated 
(1 to 1) by minimisation to receive interferon alfa-2a alone or combination therapy with interferon alfa-2a, interleukin-2, 
and ﬂ uorouracil. Treatment was not masked. The primary endpoint was overall survival. Treatment groups were 
compared with a non-stratiﬁ ed log-rank test. Analysis was by intention to treat. This study is registered, number 
ISRCTN 46518965.
Findings 502 patients were randomly assigned to receive interferon alfa-2a and 504 to receive combined treatment. 
Median follow-up was 37·2 months (24·8–52·3). Median overall survival was 18·8 months (17·0–23·2) for patients 
receiving interferon alfa-2a versus 18·6 months (16·5–20·6) for those receiving combination therapy. Overall survival 
did not diﬀ er between the two groups (hazard ratio 1·05 [95% CI 0·90–1·21], p=0·55; absolute diﬀ erence 0·3% 
(–5·1 to 5·6) at 1 year and 2·7% (–8·2 to 2·9) at 3 years). Serious adverse events were reported in 113 (23%) patients 
receiving interferon alfa-2a and 131 (26%) of those receiving combined treatment.
Interpretation Although combination therapy does not improve overall or progression-free survival compared with 
interferon alfa-2a alone, immunotherapy might still have a role because it can produce remissions that are of clinically 
relevant length in some patients. Identiﬁ cation of patients who will beneﬁ t from immunotherapy is crucial.
Funding UK Medical Research Council.
Introduction
Renal cell carcinomas account for 2% of all malignant 
tumours in adults.1 30% of patients with renal cell carci-
noma present with metastatic disease, and half of those 
who apparently have localised disease at diagnosis sub-
sequently develop metastases.2,3 Median survival for 
patients with advanced disease is 10 months and 5-year 
survival is 15%.3 The standard of care in Europe was, until 
the introduction of targeted agents, interferon alfa-2a, on 
the basis of results of several randomised trials.4–8 Findings 
of a Cochrane systematic review and meta-analysis7 con-
ﬁ rmed the superiority of interferon alfa-2a compared with 
medroxyprogesterone acetate or vinblastine. Case-control 
data and the results of the French Intergroup PERCY 
Quattro trial9 have suggested that this beneﬁ t is conﬁ ned 
to patients with good prognostic features—ie, only 20% of 
patients with metastatic disease.10–12 
Treatment with high-dose interleukin-2 has shown 
response rates of 14–23%,13–15 but, more importantly, 
about 7% of patients have a durable complete remission 
lasting longer than 3 years, some of which are maintained 
for 10 years.13–19 However, no randomised trial data have 
shown a survival advantage for this treatment compared 
with a control group.15,16 Investigators are attempting to 
ﬁ nd histopathological and molecular predictive 
markers that would allow improved selection of patients 
for this treatment (registered at Clinicaltrials.gov, 
NCT00536757).
The immunotherapy regimen that has been associated 
with the highest response rates in metastatic renal cell 
carcinoma is a combination of interferon alfa-2a, 
interleukin-2, and ﬂ uorouracil.20 Response rates as high 
as 39% have been reported,20 and results of two small 
randomised trials20,21 have shown an overall survival 
advantage compared with tamoxifen and interferon alfa-
2a plus vinblastine. However, this regimen is 
controversial since not all groups have been able to 
reproduce these high response rates. The UK Medical 
Research Council (MRC) and the European Organisation 
for Research and Treatment of Cancer (EORTC) 
therefore decided to mount a large-scale randomised 
trial comparing the then standard of care in 
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Europe—namely, interferon alfa-2a alone—with 
combined interferon alfa-2a, interleukin-2, and 
ﬂ uorouracil, with Atzpodien and colleagues’ original 
schedule.20 The primary objective of the trial was to 
compare overall survival between groups.
Methods
Participants 
RE04/30012 was an intergroup study for which the MRC 
Clinical Trials Unit was the coordinating group. The 
EORTC Genitourinary Group participated via a mailbox 
procedure with case report forms sent from EORTC sites 
to the MRC Clinical Trials Unit via the EORTC 
Headquarters. Patients were eligible for trial entry if they 
were aged older than 18 years, had histologically proven 
renal cell carcinoma, advanced metastatic disease, at least 
one measurable lesion (measured within 4 weeks of 
starting treatment), a WHO performance status of 0 or 1, 
normal haematological measures within 7 days before 
randomisation, creatinine concentrations within normal 
limits for the participating institution, and a life 
expectancy of longer than 12 weeks. Patients were 
excluded if they had received previous chemotherapy, 
endocrine therapy with biological agents, or radiotherapy 
to target lesions, had brain metastasis, unstable angina 
pectoris, or myocardial infarction within the previous 
6 months, had evidence of active infection needing 
antibiotics, had received a major organ allograft, or 
needed corticosteroids for intercurrent disease. Patients 
with previous malignant disease could be included if they 
had been disease free for longer than 5 years. We 
recommended that patients underwent resection of their 
primary tumour before entry, but this procedure was not 
mandatory. Written informed consent was obtained 
before randomisation. Ethics approval was obtained for 
RE04 through the London multicentre regional ethics 
committee (January, 2001) and via local sites for 30012. 
An independent data monitoring committee reviewed 
safety data at regular intervals.
Randomisation and masking
Randomisation was done by telephone through the MRC 
Clinical Trials Unit (London, UK) or the EORTC 
Headquarters (Brussels, Belgium). Randomisation used 
a method of minimisation to allocate patients in a 1 to 1 
ratio. Minimisation factors were centre, nephrectomy 
status, and whether metastases were at one or several 
sites. Treatment allocation was not masked.
Procedures
Written informed consent and baseline data were 
obtained before randomisation, including quality of life 
(Rotterdam Symptom Checklist, the Hospital Anxiety 
and Depression Scale, and the EuroQol Five Dimensions 
questionnaire). Tumour response was assessed with 
Response Evaluation Criteria In Solid Tumours criteria at 
weeks 9, 19, and 26 (irrespective of whether protocol 
treatment was still being received) and at the end of 
protocol treatment. Patients were clinically assessed at 8, 
10, and 12 months after randomisation, every 4 months 
in the second year, and every 6 months thereafter. Toxic 
eﬀ ects were assessed with National Cancer Institute 
Common Toxicity Criteria on day 5 of weeks 1, 4, 7, 9, 11, 
14, 17, and 19 during treatment. Quality of life assessments 
were done at baseline, 9, 19, and 26 weeks.
Patients allocated to treatment with interferon alfa-2a 
were given the drug subcutaneously three times a week 
(at MRC centres, Intron A [Schering Corporation, 
Kenilworth, NJ, USA], 10 million IU; EORTC, Roferon 
[F Hoﬀ mann-La Roche, Basel, Switzerland], 9 million 
IU). Patients assigned to combination treatment received 
interferon alfa-2a, interleukin-2, and ﬂ uorouracil 
(schedule provided in webappendix). Patients receiving 
interferon alfa-2a alone were treated until progression or 
unacceptable toxic eﬀ ects, according to investigator 
discretion. Patients allocated to combination treatment 
received a second cycle if at week 9 no unacceptable toxic 
eﬀ ects or signs of progression were reported. No more 
than two cycles were recommended. The primary 
outcome was overall survival. Secondary outcomes were 
progression-free survival and comparisons of toxic eﬀ ects, 
quality of life, and response to treatment.
Statistical analysis
The original sample size needed 510 events (deaths) 
from 670 patients to detect a 4-month (12–16 months) 
improvement in median survival with combination 
treatment, suﬃ  cient to detect a hazard ratio (HR) of 
0·75 at a 5% signiﬁ cance level and 90% power. In 2005, 
independently of the then current conﬁ dential results, 
the sample size was revised to detect a reduced target 
treatment eﬀ ect and to allow subset analyses of histology 
and nephrectomy status. The revised target was 
845 events (1100 patients), which was suﬃ  cient to detect 
an improvement in median survival from 12 to 
15 months (HR 0·8 at a 5% signiﬁ cance level and 90% 
power). The revision was made because combination 
See Online for webappendix
1006 randomised
502 allocated to interferon
alfa-2a only
15 did not receive drug
4 patient decision
2 randomised in error
1 died before treatment
1 site decision
1 site error
6 unknown
502 assessed for primary
outcome
340 deaths
504 assessed for primary
outcome
351 deaths
504 allocated to interferon
alfa-2a, interleukin-2,
and ﬂuorouracil
18 did not receive drug
5 patient decision
4 randomised in error
2 died before treatment
2 site error
5 unknown
Figure 1: Trial proﬁ le
Screening logs were not used, so the number of patients assessed for eligibility 
was not available.
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treatment was less toxic than was originally expected 
and thus a smaller treatment diﬀ erence would be 
worthwhile.
We used Stata (version 10.1) for all statistical analyses. 
Overall survival was deﬁ ned as time from randomisation 
to death from any cause; data for patients who were 
alive at last follow-up were censored at date of last 
contact. Progression-free survival was deﬁ ned as time 
from randomisation to date of ﬁ rst progression or 
death from any cause. Non-stratiﬁ ed log-rank tests 
were used to compare treatment groups. Cox models 
for treatment eﬀ ect on overall and progression-free 
survival were adjusted for WHO performance status, 
haemoglobin concentrations, and white blood cell 
counts, and transformed time from diagnosis of 
metastases to randomisation (inverse square root). 
These measures were chosen because they were 
signiﬁ cant prognostic factors in the results of the MRC 
RE01 study.8 We used the Stata program stpm22 to apply 
a ﬂ exible parametric modelling approach that allowed 
for non-proportional hazards of the treatment eﬀ ect.23 
The model was used to estimate absolute diﬀ erences in 
survival between treatment groups with time. All 
analyses were done on an intention-to-treat basis and 
all p values are two-sided.
To assess whether any treatment is more or less 
eﬀ ective dependent on binary baseline variables, we did 
a χ² test for heterogeneity. Interactions between 
treatment and continuous variables were examined with 
fractional polynomial models.24 The eﬀ ect of treatment 
according to centre size was investigated with an 
interaction test for trend. Best response to treatment 
was compared between treatment groups with a χ² test. 
Responders were deﬁ ned as patients with complete or 
part responses and non-responders as those with stable 
disease or progression. Duration of response was 
deﬁ ned as time from ﬁ rst reported response until 
disease progression or death. 
Worst toxic eﬀ ects reported overall were compared 
between treatment groups with a Mann-Whitney test. 
Binary variables (grade 0, 1, or 2 vs grade 3 or 4) were 
created for all reports of toxic eﬀ ects and Fisher’s exact 
tests were applied to compare treatment groups. 
Hypotheses were formulated and stated in the statistical 
analysis plan for four patient-reported quality-of-life 
items (tiredness, poor appetite, low energy, and shivering) 
before the start of the trial. Worst score overall was used 
so that treatment groups were of similar size (interferon 
alfa-2a alone, n=444; combined treatment, n=454). We 
Interferon alfa-2a 
(n=502)
Combined treatment* 
(n=504)
Age
Median (years; range) 58 (23–82) 57 (20–81)
Unknown 0 0
Sex
Male 355 (71%) 385 (76%)
Female 143 (28%) 116 (23%)
Unknown 4 (1%) 3 (1%)
WHO performance status
0 271 (54%) 300 (60%)
1 230 (46%) 204 (40%)
Unknown 1 (<1%) 0
Nephrectomy
No 52 (10%) 52 (10%)
Yes 449 (89%) 452 (90%)
Unknown 1 (<1%) 0
Metastases
One site 142 (28%) 163 (32%)
Several sites 358 (71%) 341 (68%)
Unknown 2 (<1%) 0
MSKCC risk group†
Low‡ (%) 34 (7%) 41 (8%)
Medium§ (%) 289 (58%) 302 (60%)
High¶ (%) 95 (19%) 84 (17%)
Unknown (%) 84 (17%) 77 (15%)
MSKCC=Memorial Sloan-Kettering Cancer Centre. *Interferon alfa-2a, interleukin-2, 
and ﬂ uorouracil. †High-risk factor deﬁ ned as: WHO performance status greater 
than 2; lactate dehydrogenase concentration higher than 300 IU/L; haemoglobin 
concentration less than 13 g/dL for men or 11·5 g/dL for women; calcium 
concentration lower than 9 mg/dL or higher than 11 mg/dL; time from initial 
diagnosis of metastatic renal cell carcinoma to treatment containing interferon 
alfa-2a of less than a year. ‡No risk factors. §One or two risk factors. ¶Three, four, or 
ﬁ ve risk factors.
Table 1: Baseline characteristics (including retrospective grouping of 
patients according to Memorial Sloan-Kettering Cancer Centre criteria)
Interferon alfa-2a 
(n=502)
Combined treatment* 
(n=504)
Total 
(n=1006)
Overall survival
Alive (%) 162 (32%) 153 (30%) 315 (31%)
Dead (%) 340 (68%) 351 (70%) 691 (69%)
Cause of death
Metastatic RCC 326 335 661
Treatment-related 2 4 6
Other 12 11 23
Unknown 0 1 1
Progression-free survival
Alive and without progression (%) 38 (8%) 47 (9%) 85 (9%)
Progression only (%) 124 (25%) 106 (21%) 230 (23%)
Died without progression (%) 36 (7%) 32 (6%) 68 (7%)
Progressed and died (%) 304 (61%) 319 (63%) 623 (62%)
Response
Complete response (%) 11 (2%) 11 (2%) 22 (2%)
Part response (%) 62 (12%) 97 (19%) 159 (16%)
Stable disease (%) 237 (47%) 211 (42%) 448 (45%)
Progressive disease (%) 148 (29%) 143 (28%) 291 (29%)
Unknown (%) 44 (9%) 42 (8%) 86 (9%)
RCC=renal cell carcinoma. *Interferon alfa-2a, interleukin-2, and ﬂ uorouracil.
Table 2: Summary of events
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used Mann-Whitney tests to assess these hypotheses by 
comparing worst scores by treatment group.
All patients were grouped retrospectively according to 
the widely used Memorial Sloan-Kettering Cancer 
Centre criteria (MSKCC).12 MSKCC risk groups are 
approxi mations for our data because groupings are 
based on thresholds that were deﬁ ned by Motzer and 
colleagues,25 but laboratory normal ranges for con-
centrations of lactate dehydrogenase and haemoglobin 
were not obtained at randomisation and some blood 
measurements were missing. 
This study is registered, number ISRCTN 46518965.
Role of the funding source
The MRC and EORTC reviewed and approved the study 
design. The study sponsor, the MRC, had no role in the 
conduct of the study or in writing this report. The 
corresponding author had full access to all study data 
and had responsibility for the decision to submit for 
publication.
Results
The trial opened to accrual in April, 2001, and closed in 
August, 2006. 1006 patients were randomly allocated to 
treatment (707 MRC, 299 EORTC) from 50 centres across 
the UK, Holland, Slovakia, Germany, Belgium, and 
Denmark. 502 patients were allocated to receive interferon 
alfa-2a and 504 to receive combined treatment (ﬁ gure 1). 
Table 1 shows patients’ characteristics. We note that a 
high proportion of patients had undergone nephrectomy 
before study entry. 
Median duration of treatment for patients receiving 
interferon alfa-2a was 127 days (range 3–1803). 118 (24%) 
patients received the drug for 3–6 months, 114 (23%) for 
6–12 months, and 47 (10%) for longer than 12 months. 
138 (29%) patients receiving interferon alfa-2a alone had 
a dose modiﬁ cation, and 102 (21%) had a break in 
treatment (webappendix). However, only 56 (12%) 
patients received less than 60% of the target dose. The 
most common causes of dose modiﬁ cation in patients 
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Figure 2: Kaplan-Meier plots of (A) overall survival and (B) progression-free survival for patients receiving 
interferon alfa-2a or combined treatment*
*With interferon alfa-2a, interleukin-2, and ﬂ uorouracil.
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Figure 3: Absolute diﬀ erence between treatments for (A) overall survival and 
(B) progression-free survival 
Values greater than zero show improved survival with combined treatment. 
95% CIs are for the diﬀ erence between treatment with interferon alfa-2a alone 
and combined treatment with interferon alfa-2a, interleukin-2, and ﬂ uorouracil. 
Red line shows no diﬀ erence between treatment groups. KM=Kaplan-Meier.
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receiving interferon alfa-2a were lethargy or depression 
(63 patients, 13%), nausea or haematological toxic eﬀ ects 
(eight and ten patients, both 2%), and neurotoxic eﬀ ects 
(seven patients, 1%). 50 (10%) patients had dose 
modiﬁ cations for other or several reasons. 
For patients receiving combined treatment, median 
duration of a treatment cycle was 54 days (range 2–138) 
and median duration of trial treatment was 57 days 
(2–222). 486 (96%) patients started cycle one, 192 (38%) 
started cycle two, three (1%) went on to receive a third 
cycle, and one (<1%) a fourth cycle. In cycle one, 
140 (29%) patients had a dose modiﬁ cation for interferon 
alfa-2a, 118 (24%) for interleukin-2, and 105 (22%) for 
ﬂ uorouracil; in cycle two, these values were 64 (33%), 
66 (34%), and 59 (31%), respectively. Haematological 
toxic eﬀ ects, lethargy or depression, and other or several 
reasons were the most common causes of dose 
modiﬁ cation in patients receiving combined treatment. 
221 (45%) patients had a break in treatment during 
cycle 1 and 71 (37%) in cycle two (webappendix). For 
cycle 1, 278 (57%), 312 (64%), and 253 (52%) patients 
received 80% or more of their expected dose for 
interferon alfa-2a, interleukin-2, and ﬂ uorouracil, 
respectively.
Analysis was done at a median follow-up of 37·2 months 
(24·8–52·3) and when 691 participants had died 
(340 patients receiving interferon alfa-2a, 351 receiving 
combined treatment). The data were locked for analysis 
on Sept 12, 2008. Table 2, ﬁ gure 2, and ﬁ gure 3 show a 
summary of results. We noted no evidence of a diﬀ erence 
between treatment groups for overall survival (HR 1·05 
[95% CI 0·90–1·21]; p=0·55). Overall survival at 1 year 
was 67% (62–71) for patients receiving interferon alfa-2a 
and 67% (63–71) for combined treatment. At 3 years, 
overall survival was 30% (26–35) in the interferon alfa-2a 
group and 26% (22–30) in the combined group. Absolute 
diﬀ erence in overall survival between groups was 0·3% 
(–5·1 to 5·6) at 1 year and 2·7% (–8·2 to 2·9) at 3 years. 
Median survival of patients given interferon alfa-2a alone 
was 18·8 months (17·0–23·2) versus 18·6 months 
(16·5–20·6) for those in the combined group.
At the time of analysis, 921 participants had progression 
of disease or had died (interferon alfa-2a, 464; combined 
treatment, 457). There was no evidence that progression-
free survival diﬀ ered between treatment groups (HR 1·02 
[0·89–1·16]; p=0·81). Median progression-free survival 
in patients receiving interferon alfa-2a alone was 
5·5 months (4·3–6·2) compared with 5·3 months 
(4·8–6·0) in those on combined treatment. The 
robustness of the results was examined with Cox models 
adjusted for prognostic factors that were shown to be 
signiﬁ cant by results of the MRC RE01 study. Adjusted 
and unadjusted models showed similar results (overall 
survival, adjusted HR 1·12 [0·96–1·30], p=0·14; 
progression-free survival, 1·03 [0·90–1·17], p=0·69).
The best overall response rate in patients receiving 
combined treatment was signiﬁ cantly higher than in 
patients receiving interferon alfa-2a alone (108 of 
462 patients [23%] vs 73 of 458 [16%]; p=0·0045). Complete 
response to treatment was recorded in 11 patients 
receiving interferon alfa-2a (median duration 
15·6 months, IQR 5·3–not reached) and 11 on combined 
treatment (median duration not reached). One patient 
with a complete response who was allocated to combined 
treatment did not receive all three drugs, but rather 
interferon alfa-2a alone because of a mistake by the 
treatment centre. Complete remissions were durable in 
four patients who received only interferon alfa-2a (>14, 
>26, >44, and >55 months) and in eight patients who 
received combined therapy (>9, >12, >48, >53, >54, >59, 
>65, and >78 months). 
Exploratory analyses to examine interactions between 
treatment and baseline factors showed no evidence of 
interactions for overall survival. Outcomes for patients 
receiving complex immunotherapies might be better 
when delivered by large specialist centres. Therefore, 
patients were classiﬁ ed according to the number 
randomised by a centre: fewer than nine, ten to 20, or 
greater than 20 patients. The eﬀ ect of combined treatment 
was not related to centre (data not shown). 
Median overall survival (months; 95% CI) 1-year overall survival (%) 3-year overall survival (%)
Motzer and co-workers12 RE04/30012 Motzer and co-workers12 RE04/ 30012 Motzer and co-workers12 RE04/30012
Low* 29·6 (20·9–37·8) 32·8 (26·8–42·9) 83% 86% 45% 46%
Medium† 13·8 (12·4–15·9) 21·6 (18·7–24·0) 58% 71% 17% 29%
High‡ 4·9 (4·3–6 ·3) 9·3 (8·0–11·7) 20% 43% 2% 13%
For RE04/30012: 75, 591, and 179 patients in low, medium, and high risk groups, respectively. *No risk factors. †One or two risk factors. ‡Three, four, or ﬁ ve risk factors.
Table 3: Overall survival in RE04/30012 compared with data from Motzer and colleagues,12 by Memorial Sloan-Kettering Cancer Centre risk group
Interferon alfa-2a 
(n=502)
Combined treatment* 
(n=504)
None 2 (<1%) 0
Grade 1 98 (20%) 32 (6%)
Grade 2 197 (39%) 178 (35%)
Grade 3 169 (34%) 229 (45%)
Grade 4 14 (3%) 40 (8%)
Unknown 22 (4%) 25 (5%)
*Interferon alfa-2a, interleukin-2, and ﬂ uorouracil. 
Table 4: Worst toxic eﬀ ects reported during treatment, by Common 
Toxicity Criteria grade
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Survival of patients by MSKCC prognostic category 
compared favourably with published data (table 3). A 
prognostic model was developed from RE01, our previous 
trial in metastatic renal cell carcinoma, which compared 
treatment with interferon alfa-2a alone with treatment 
with medroxyprogesterone acetate. The model took into 
account WHO performance status, haemoglobin, white 
blood cell count, and time from diagnosis of metastatic 
disease to randomisation. Three prognostic categories 
were deﬁ ned (good, intermediate, and poor), and median 
survival of patients in RE04/30012 was better than for 
those in RE01 for all prognostic groups (good, 37·3 vs 
15·5 months; intermediate, 19·3 vs 9·0 months, and 
poor, 8·0 vs 2·2 months). The explanation is uncertain, 
although this ﬁ nding might be an example of how 
survival from cancer can improve with advances in 
supportive care.
Post-protocol antitumour treatment data were obtained 
and seven (1%) patients receiving interferon alfa-2a 
alone crossed over to the triple regimen and 53 (11%) on 
combined treatment were subsequently given single-
agent interferon alfa-2a. For interferon alfa-2a alone, 
25 patients received medroxyprogesterone acetate, 
106 underwent radiotherapy, 25 had surgery, and 
242 received other post-progression treatment, compared 
with 31, 121, 23, and 233 patients, respectively, in the 
combined group. Of patients who received other post-
progression treatment, 281 (28%) received a targeted 
agent (151 [30%] receiving interferon alfa-2a and 
130 [26%] on combined treatment). 
Table 4 and table 5 show results for toxic eﬀ ects of 
treatment. During treatment signiﬁ cantly more grade 3 
and 4 toxic eﬀ ects were associated with combined 
treatment than with interferon alfa-2a alone (269 patients 
[53%] vs 183 patients [36%]; p<0·0001). Fatigue was 
appreciably worse for patients receiving combined 
treatment, with 106 (22%) of 479 patients reporting 
grade 1 fatigue, 214 (45%) grade 2, 113 (23%) grade 3, 
and nine (2%) grade 4, compared with 161 (34%), 186 
(39%), 83 (17%), and two (<1%) for those receiving 
interferon alfa-2a. We noted no evidence for diﬀ erences 
between treatment groups in worst quality of life score 
for tiredness, poor appetite, shivering, or low energy. 
Serious adverse events were reported in 113 (23%) 
patients receiving interferon alfa-2a and 131 (26%) of 
those receiving combined treatment.
Discussion
The results of our large trial clearly show that combined 
treatment with interferon alfa-2a, interleukin-2, and 
ﬂ uorouracil provides no advantage compared with 
interferon alfa-2a alone in terms of overall or progression-
free survival. However, the overall response rate was 
higher in patients receiving combined treatment than in 
those receiving interferon alfa-2a alone, although the 
response rate for combined treatment was 23%, which is 
not nearly as high as the 39% reported by Atzpodien and 
colleagues.20 Treatment was well tolerated and toxic 
eﬀ ects were manageable. Combined treatment was 
associated with more severe toxic eﬀ ects overall than was 
treatment with interferon alfa-2a alone. The median 
duration of treatment with interferon alfa-2a for patients 
in our study (4·2 months) was similar to those reported 
for the interferon alfa-2a control groups of other ﬁ rst-line 
studies.26,27 
Dose modiﬁ cations and breaks occurred with both 
regimens, but breaks were more frequent for patients 
receiving combined therapy than for those receiving 
interferon alfa-2a. Three-quarters of patients given 
interferon alfa-2a alone received 80% or more of their 
expected dose. Reductions were more common for those 
receiving combined treatment. The high degree of dose 
reduction with combined therapy could be a reason for 
the absence of beneﬁ t for this regimen. However, we 
believe that this ﬁ nding is representative of the feasibility 
of this treatment, and no diﬀ erence existed between the 
treatments according to size or experience of the treating 
centre. Atzpodien and colleagues20 reported that 23% of 
patients went on to a third cycle of combined therapy. 
Our decision to limit the total number of cycles to two 
was made after wide consultation with physicians at 
major cancer centres in which cytokine therapies are 
used, including combined interferon alfa-2a, 
interleukin-2, and ﬂ uorouracil, for metastatic renal cell 
carcinoma. Despite this consultation, our study could be 
criticised for not administering combined therapy for an 
adequate number of cycles.
We obtained post-progression treatment information, 
which was reasonably balanced between the two 
treatment groups. The survival of patients with low risk 
prognostic factors in RE04/30012 was similar to the 
MSKCC prognostic model dataset (median survival 
32·8 months for RE04/30012 and 29·6 months for 
MSKCC). Patients with medium and high risk 
Grade 3/4 p value
Interferon alfa-2a (n=480) Combined treatment* (n=479)
Fatigue or malaise† 85 (18%) 122 (25%) 0·0046
Leucopenia† 6 (1%) 32 (7%) <0·0001
Febrile neutropenia† 4 (1%) 22 (5%) 0·0005
Nausea 16 (3%) 26 (5%) 0·12
Diarrhoea† 3 (1%) 17 (4%) 0·0013
Dyspnoea 18 (4%) 18 (4%) 1·00
Fever† 2 (<1%) 19 (4%) 0·0001
Hypotension† 1 (<1%) 18 (4%) <0·0001
Vomiting 11 (2%) 18 (4%) 0·19
Cutaneous skin reaction† 2 (<1%) 12 (3%) 0·0070
Anaemia 16 (3%) 10 (2%) 0·24
Only symptoms with greater than 1% incidence in at least one group are shown. *Interferon alfa-2a, interleukin-2, and 
ﬂ uorouracil. †Comparison between treatment groups was signiﬁ cant when Fisher’s exact test applied.
Table 5: Common Toxicity Criteria grade 3 and 4 toxic eﬀ ects reported in both treatment groups, 
by symptom
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prognostic categories in RE04/30012 had a better 
outlook than was suggested by the prognostic model 
(table 3). This ﬁ nding could be because none of the 
RE04/30012 patients had all ﬁ ve risk factors, since 
WHO performance status of greater than 1 was an 
exclusion criterion.
The predeﬁ ned number of events was not reached; 
however, with 691 events at the time of analysis our 
conclusions have been made on the basis of a large 
amount of information. The Kaplan-Meier plots show 
no long-term treatment eﬀ ect, and no discernible 
biological reason exists for why a diﬀ erence between 
treatment groups might occur only after more events 
have accrued. Publication of these results in a timely 
manner was important. 
Targeted agents have become standard of care for ﬁ rst-
line treatment of patients with metastatic renal cell 
carcinoma, on the basis of results of three randomised 
trials,26–28 all of which used interferon alfa-2a alone as 
control. Two of these trials have shown large beneﬁ ts for 
targeted therapies compared with single-agent interferon 
alfa-2a, with HRs for progression-free survival of 
0·42–0·63.26,27 Overall survival could also be signiﬁ cantly 
improved by these novel agents; patients who received 
temsirolimus alone in a ﬁ rst-line study with three groups 
had longer overall survival than did those receiving 
interferon alfa-2a alone (HR 0·73; p=0·008), and 
sunitinib has an overall survival advantage compared 
with interferon alfa-2a (p=0·051).29,30 Our results are 
important because they show that single-agent interferon 
was the correct control treatment to use in these pivotal 
trials that have deﬁ ned the role of targeted agents. If we 
had shown combined treatment to be better than 
monotherapy, then these trials would have had to be re-
run with combined interferon alfa-2a, interleukin-2, and 
ﬂ uorouracil as control treatment.
None of the novel targeted agents seem to be curative, 
and immunotherapy remains the only curative treatment 
available for patients with metastatic renal cell carcinoma, 
albeit in a very few patients. We noted complete 
remissions in both treatment groups, which were durable 
in 12 patients. This ﬁ nding is of clinical relevance because 
high-dose intravenous interleukin-2 is often stated to be 
the only therapy that is associated with durable complete 
remissions in metastatic disease. Our data show that this 
drug is not the only one to be associated with complete 
remission, although we report a reduced rate of complete 
remission with the treatments given in our trial. A 
subgroup of patients might exist who could beneﬁ t from 
starting therapy with an immunotherapeutic drug rather 
than a targeted agent. 
Contributors
CLG contributed to data analysis and drafted the report. PMP was 
involved in patient recruitment, data interpretation, and review of the 
report. MA entered patients into the trial and contributed to the report. 
NJ contributed to patient recruitment and drafting of the report. RTDO 
entered patients into the trial and contributed to editing of the report. 
TH contributed to drafting of the report. RS was the responsible 
statistician for the EORTC and participated in study design and conduct 
for the EORTC. MKBP contributed to study design and analysis and 
commented on the report. PR contributed to design aspects, sample-size 
calculation, scientiﬁ c overview of the trial, and leading of the project, 
and commented on the report. PFAM contributed to study design, 
patient recruitment, data interpretation, and editing of the report. MEG 
contributed to concept and design of the trial, patient recruitment, data 
interpretation, and writing and approval of report. BH contributed to 
patient recruitment and was a member of the writing committee for the 
report. LP contributed as a research nurse to recruit patients and 
drafting the report. JM contributed to patient recruitment and 
commenting on the report.
The RE04/30012 study group 
Trial management group Prof Martin Gore, Lynda Pyle (Royal Marsden 
Hospital, London, UK); Prof Poulam Patel (University of Nottingham, 
Nottingham, UK); Prof Nick Thatcher (Christie Hospital, Manchester, 
UK); Prof Peter Mulders (EORTC member, Netherlands); 
Prof Patrick Royston (MRC Clinical Trials Unit, London, UK).
Data analysis Royston P, Griﬃ  n C L, Chung C.
Independent data monitoring committee J Joﬀ e (chair), K Wheatley, M Lind.
Trial steering committee D Guthrie, C McArdle, H Earl, J Scholeﬁ eld, 
R Cowan.
Trial and Data Management T Hussain, A Griﬃ  ths, W Cragg, T Barlow, 
J Jenkins (MRC Clinical Trials Unit, London, UK); R Sylvester, 
I Claessens, S Marreaud (EORTC Headquarters, Brussels, Belgium).
RE04 clinical centres (investigators): UK Aberdeen Royal Inﬁ rmary 
(D Bissett); Addenbrookes Hospital, Cambridge (K Fife); Beatson 
Oncology Centre, Glasgow (M Aitchison); Bristol Haematology and 
Oncology Centre (P Wilson); Cheltenham General Hospital (D Farrugia); 
Christie Hospital, Manchester (R Hawkins); Clatterbridge Centre for 
Oncology (E Marshall); Derbyshire Royal inﬁ rmary (P Chakraborti); Essex 
County Hospital (B Sizer); Glan Clwyd Hospital (A B W Nethersell); 
Guy’s Hospital (P G Harper); James Cook University Hospital, 
Middlesborough (A Humphreys); Leicester Royal Inﬁ rmary (W Steward); 
Mount Vernon Hospital, Middlesex (P Nathan, N Shah); Newcastle 
General Hospital (J T Roberts); New Cross Hospital, Wolverhampton 
(A Samanci); Princess Royal Hospital, Hull (A Maraveyas); Queen 
Elizabeth Hospital, Birmingham (N D James); Royal Berkshire Hospital 
(P Rogers); Royal Bournemouth Hospital (T H Hickish); Royal Devon 
and Exeter Hospital, Wonford (D Sheehan); Royal Free Hospital 
(D Chao); Royal Marsden Hospital, London (M E Gore); Royal Marsden 
Hospital, Sutton (M E Gore); Royal Surrey County Hospital (S Houston); 
Royal Sussex Hospital, Brighton (A Webb); Southampton General 
Hospital (G M Mead); Southend General Hospital, Southend 
(S Nicholson); St Bartholomew’s Hospital, London (R T D Oliver); 
St George’s Hospital, London (A Dagleish); St. James’ Hospital, Leeds 
(P Selby); St Mary’s Hospital, Portsmouth (J Gale); Taunton and Somerset 
Hospital (P Wilson); Torbay District General Hospital (A Lydon); Velindre 
Hospital, Cardiﬀ  (J Barber); Western General Hospital, Edinburgh 
(D McLaren); Western Inﬁ rmary, Glasgow (J Graham); Weston Park 
Hospital, Sheﬃ  eld (B Hancock); Denmark Rigshopitalet/Frederiksberg 
Hospital (G G Hermann).
EORTC centres (investigators): Holland Academisch Ziekenhuis 
Maastricht (P Hupperets); Erasmus Mc (R De Witt); Institute Jules 
Bordet (R Van Velthoven); Leiden University Medical Centre (S Osanto); 
University Medical Centre Nijmegen (P Mulders); Slovakia National 
Cancer Institute (J Mardiak); Germany Staedtkrankenhaus Kassel 
(P Albers), Universitaetskliniken Bonn (P Albers); Belgium Akademisch 
Ziekenhuis Vub (F Keuppens); Onze Lieve Vrouw Ziekenhuis 
(P Carpentier); Uz Antwerp (L Hoekx), Uz Leuven (V Oosterom, T Allan).
Conﬂ icts of interest
CLG, BH, PP, MA, NJ, RTDO, JM, TH, RS, MKBP, PR, and PFAM 
declare that they have no conﬂ icts of interest. MEG has participated in 
speaker bureaus and advisory boards for Roche, Pﬁ zer, Bayer, and 
GlaxoSmithKline. LP has received travel grants from Pﬁ zer and Bayer 
Schering and honoraria from Pﬁ zer.
Acknowledgments 
We thank all patients who participated in this trial and the research staﬀ  
at the clinical centres, who helped to recruit participants and provide 
Articles
648 www.thelancet.com   Vol 375   February 20, 2010
data. This report was supported by grants numbers 5U10 CA11488-32 to 
5U10 CA011488-38 from the National Cancer Institute (Bethesda, MD, 
USA) and the EORTC Charitable Trust. Its contents are solely the 
responsibility of the authors and do not necessarily represent the oﬃ  cial 
views of the National Cancer Institute. Schering-Plough provided free 
interferon and Chiron provided interleukin-2 at a discounted rate to 
MRC centres. Roche AG and Chiron provided support to the EORTC. 
MG acknowledges UK National Health Service funding to the National 
Institute for Health Research Biomedical Research Centre at the Royal 
Marsden Hospital.
References
1 Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002: Cancer 
incidence, mortality and prevalence worldwide. IARC CancerBase 
No. 5, version 2.0. Lyon: IARCPress, 2004.
2 De Mulder PH, van Herpen CM, Mulders PA. Current treatment of 
renal cell carcinoma. Ann Oncol 2004; 15 (suppl 4): 319–28.
3 Harkins D, Krapcho M, Mariotto A, et al, eds. National Cancer 
Institute. SEER cancer statistics review, 1975–2002. http://seer.
cancer.gov/csr/1975_2002/ (accessed Feb 15, 2007).
4 Kriegmair M, Oberneder R, Hofstetter A. Interferon alfa and 
vinblastine versus medroxyprogesterone acetate in the treatment of 
metastatic renal cell carcinoma. Urology 1995; 45: 758–62.
5 Pyrhönen S, Salminen E, Ruutu M, et al. Prospective randomized 
trial of interferon alfa-2a plus vinblastine versus vinblastine alone 
in patients with advanced renal cell cancer. J Clin Oncol 1999; 
17: 2859–67.
6 Steineck G, Strander H, Carbin BE, et al. Recombinant leukocyte 
interferon alpha-2a and medroxyprogesterone in advanced renal cell 
carcinoma. A randomized trial. Acta Oncol 1990; 29: 155–62.
7 Coppin C, Porzsolt F, Awa A, Kumpf J, Goldman A, Wilt T. 
Immunotherapy for advanced renal cell cancer. 
Cochrane Database Syst Rev 2005; 1: CD001425.
8 Medical Research Council Renal Cancer Collaborators. (1999) 
Interferon-α and survival in metastatic renal carcinoma: early 
results of a randomised controlled trial. Lancet 1999; 353: 14–17. 
9 Negrier S, Perol D, Ravaud A, et al, for the French Immunotherapy 
Intergroup. Medroxyprogesterone, interferon alfa-2a, interleukin 2, 
or combination of both cytokines in patients with metastatic renal 
carcinoma of intermediate prognosis: results of a randomized 
controlled trial. Cancer 2007; 110: 2468–77. 
10 Jones M, Philip T, Palmer P, et al. The impact of interleukin-2 on 
survival in renal cancer: a multivariate analysis. 
Cancer Biother Radiopharm 1993; 8: 275–88.
11 Fossa S, Jones M, Johnson P, et al. Interferon-alpha and survival in 
renal cell cancer. Br J Urol 1995; 76: 286–90.
12 Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-
Alfa as a Comparative Treatment for Clinical Trials of New 
Therapies Against Advanced Renal Cell Carcinoma. J Clin Oncol 
2002; 20: 289–96. 
13 Fisher RI, Rosenberg SA, Fyfe G. Long-term survival update for 
high-dose recombinant interleukin-2 in patients with renal cell 
carcinoma. Cancer J Sci Am 2000; 6: S55–57.
14 Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, 
Louie AC. Results of treatment of 255 patients with metastatic renal 
cell carcinoma who received high-dose recombinant interleukin-2 
therapy. J Clin Oncol 1995; 13: 688–96.
15 McDermott DF, Regan MM, Clark JI, et al. Randomized phase III 
trial of high-dose interleukin-2 versus subcutaneous interleukin-2 
and interferon in patients with metastatic renal cell carcinoma. 
J Clin Oncol 2005; 23: 133–41.
16 Yang JC, Sherry RM, Steinberg SM, et al. Randomized study of 
high-dose and low-dose interleukin-2 in patients with metastatic 
renal cancer. J Clin Oncol 2003; 21: 3127–32.
17 Rosenberg SA, Yang JC, White DE, Steinberg SM. Durability of 
complete responses in patients with metastatic cancer treated with 
high-dose interleukin-2: identiﬁ cation of the antigens mediating 
response. Ann Surg 1998; 228: 307–19.
18 Figlin R, Gitlitz B, Franklin J, et al. Interleukin-2-based 
immunotherapy for the treatment of metastatic renal cell 
carcinoma: an analysis of 203 consecutively treated patients. 
Cancer J Sci Am 1997; 3: S92–97.
19 Atkins MB, Regan M, McDermott D. Update on the role of 
interleukin 2 and other cytokines in the treatment of patients with 
stage IV renal carcinoma. Clin Cancer Res 2004; 10: 6342S–46S.
20 Atzpodien J, Kirchner H, Illiger HJ, et al. IL-2 in combination with 
IFN-alpha and 5-FU versus tamoxifen in metastatic renal cell 
carcinoma: long-term results of a controlled randomized clinical 
trial. Br J Cancer 2001; 85: 1130–36.
21 Atzopdien J, Kirchner H, Jonas U, et al. Interleukin-2 and 
interferon alfa-2a based immunotherapy in advanced renal cell 
carcinoma: a prospectively randomised trial of the German 
Cooperative Renal Carcinoma Chemoimmunotherapy Group 
(DGCIN). J Clin Oncol 2004; 22: 1188–94.
22 Royston P. Flexible parametric alternatives to the Cox model, and 
more. Stata J 2001; 1: 1–28.
23 Royston P, Parmar M. Flexible parametric proportional-hazards and 
proportional-odds models for censored survival data, with 
application to prognostic modelling and estimation of treatment 
eﬀ ects. Stat Med 2002; 21: 2175–97.
24 Royston P, Sauerbrei W. A new approach to modelling interactions 
between treatment and continuous covariates in clinical trials by 
using fractional polynomials. Stat Med 2004; 23: 2509–25.
25 Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. 
Survival and prognostic stratiﬁ cation of 670 patients with advanced 
renal cell carcinoma. J Clin Oncol 1999; 17: 2530–40.
26 Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon 
alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 
356: 115–24.
27 Escudier B, Pluzanska A, Koralewski P, et al, for the AVOREN Trial 
investigators. Bevacizumab plus interferon alfa-2a for treatment of 
metastatic renal cell carcinoma: a randomised, double-blind 
phase III trial. Lancet 2007; 370: 2103–11. 
28 Escudier B, Szczylik C, Hutson TE, et al. Randomized phase II trial 
of ﬁ rst-line treatment with sorafenib versus interferon Alfa-2a in 
patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 
27: 1280–89.
29 Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and 
updated results for sunitinib compared with interferon alfa in 
patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 
27: 3584–90.
30 Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon 
alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 
356: 2271–81.
